title: Carcinoma of the anus: strategies in management.
abstract: The management of anal cancer underwent an interesting transformation over the last two decades. Prior to this period, the standard definitive treatment for carcinoma of the anal canal was abdominal-perineal resection, which necessitated a permanent colostomy. The organ preservation concept appeared following the discovery of a high complete response rate from preoperative combined chemoradiation prior to abdominal-perineal resection. The organ preservation method of treatment rapidly gained popularity and ultimately saved a large number of patients from undergoing abdominal-perineal resection and colostomy. Chemoradiation treatment itself subsequently went through an evolutionary process. Several studies have sought to define the optimal chemotherapeutic regimen as well as radiation treatment dose and fractionation. Ongoing studies attempt to define an optimal treatment regimen that yields a higher cure rate while minimizing toxicity. We review the etiology, epidemiology, and treatment regimens for anal cancer.
authors.affiliation: Emory University School of Medicine, Department of Radiation Oncology, Atlanta, Georgia, USA.
authors.forename: Natia
authors.initials: N
authors.lastname: Esiashvili
authors.forename: Jerome
authors.initials: J
authors.lastname: Landry
authors.forename: Richard H
authors.initials: RH
authors.lastname: Matthews
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001005:Anus Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D002277:Carcinoma / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D002986:Clinical Trials as Topic; D003125:Colostomy; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011878:Radiotherapy; D012307:Risk Factors; D013514:Surgical Procedures, Operative